CollPlant Biotechnologies Ltd. — Form 6-K Summary
Business Context and Reporting Period
CollPlant Biotechnologies Ltd., an Israeli foreign private issuer, furnished a Form 6-K for September 2026. The filing was submitted on September 22, 2026 and reports the issuance of a press release regarding Nasdaq listing compliance.
Key Financial Metrics
The filing does not provide revenue, profitability, cash flow, margins, debt, liquidity, or other operating or financial metrics.
Material Changes Versus Prior Period
The company announced that it had regained compliance with Nasdaq’s minimum bid price requirement. The filing does not state the prior deficiency period, the specific bid-price history, or whether any other listing conditions remain outstanding.
Guidance, Outlook, Risks, and Unusual Items
No financial guidance, operating outlook, management forecast, risk updates, contingencies, or unusual accounting items are disclosed in the provided filing text.
The Form 6-K and attached Exhibit 99.1 are incorporated by reference into specified registration statements on Forms S-8 and F-3.
Important Facts for Investors to Verify
- Review Exhibit 99.1 for the precise terms and date of Nasdaq’s compliance determination.
- Verify whether the company must continue meeting the minimum bid price requirement for a specified monitoring period.
- Confirm whether any other Nasdaq listing deficiencies or potential delisting risks remain.
- Consult the company’s next periodic report for updated financial results, liquidity, capital needs, and business developments.